UK Vaccines Market
The UK vaccines market was valued at $1.4 billion in 2023 and is projected to reach $3.0 billion by 2033, growing at a CAGR of 7.7% from 2024 to 2033.
A vaccine is a biological substance administered to protect individuals against infectious and potentially life-threatening diseases. It contains either the whole or a specific component of viruses, bacteria, or toxins responsible for diseases. Vaccines work by stimulating the immune system to trigger a defense against these pathogens without causing the disease. Key components of a vaccine include antigens, adjuvants, stabilizers, and preservatives. There are various types of vaccines, each designed to stimulate the immune system in different ways, such as inactivated vaccines, subunit vaccines, live attenuated vaccines, toxoid vaccines, and DNA or mRNA vaccines.
Increase in public health campaigns and free immunization initiatives by the National Health Service is a key driver of the UK vaccines market. In addition, rise in awareness among individuals regarding the importance of vaccination, particularly after the COVID-19 pandemic, has propelled the development of the market. A notable trend gaining prominence in the market in recent times is the formation of compound vaccines. These vaccines comprise varying antigens from bacteria, viruses, and other microorganisms, resulting in the development of one formulation offering protection against multiple diseases.
However, the extensive approval process established by the UK Medicines and Healthcare products Regulatory Agency for the commercialization of new vaccines hampers the development of the market. Furthermore, rise in the prevalence of disease variants due to frequent mutations in microorganisms restrains the market growth significantly. On the contrary, rise in the inclination of medical facilities and government in the UK toward developing vaccines for chronic diseases is projected to present remunerative opportunities for the market. For instance, The BMJ - a British publisher of medical journals - states that the UK is poised to become a hotbed of cancer vaccine trials as around 30 British hospitals have signed up to be part of the Cancer Vaccine Launch Pad in 2024.
Segment Review
The UK vaccines market is segmented into technology type, indication, and end user. On the basis of technology type, the market is divided into inactivated vaccines, toxoid vaccines, recombinant & conjugate vaccines, live attenuated vaccines, and others. As per indication, it is classified into pneumococcal disease; influenza; human papilloma virus; meningococcal disease; rotavirus; varicella; measles, mumps, & rubella; diphtheria, pertussis, & tetanus (DTP); polio; hepatitis; and other indications. By end user, it is categorized into pediatric, adults, and travelers.Key Findings
On the basis of technology type, the recombinant & conjugate vaccines segment was the highest shareholder in 2023.Depending on indication, the human papilloma virus segment held a notable share of the market in 2023.
As per end user, the pediatric segment dominated the market in 2023.
Competition Analysis
The major players in the global UK vaccines market include Pfizer, Valneva SE, Viatris Inc., AstraZeneca, Emergex Vaccines, Sanofi, Bavarian Nordic A/S, Prokarium, Merck & Co., Inc., and GSK plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.Additional benefits you will get with this purchase are:
- Quarterly Update* (with the purchase of an enterprise license)
- 5 additional Company Profiles, pre- or post-purchase, as a free update.
- Free Updated Version (once released) with the purchase of an enterprise user license.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Technology Type
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant and Conjugate Vaccines
- Live Attenuated Vaccines
- Others
By Indication
- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella
- Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DTP)
- Polio
- Hepatitis
- Other Indications
By End User
- Pediatric
- Adults
- Travelers
Key Market Players
- Pfizer
- Valneva SE
- Viatris Inc.
- AstraZeneca
- Emergex Vaccines
- Sanofi
- Bavarian Nordic A/S
- Prokarium
- Merck & Co., Inc.
- GSK plc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: UK VACCINES MARKET, BY TECHNOLOGY TYPE
CHAPTER 5: UK VACCINES MARKET, BY INDICATION
CHAPTER 6: UK VACCINES MARKET, BY END USER
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Pfizer
- Valneva SE
- Viatris Inc.
- AstraZeneca
- Emergex Vaccines
- Sanofi
- Bavarian Nordic A/S
- Prokarium
- Merck & Co., Inc.
- GSK plc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | November 2024 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 1.4 billion |
| Forecasted Market Value ( USD | $ 3 billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | United Kingdom |
| No. of Companies Mentioned | 10 |
